What is Leerink Partnrs’ Estimate for KROS Q2 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings estimates for Keros Therapeutics in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($1.02) per share for the quarter. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.66) EPS and Q4 2025 earnings at ($0.63) EPS.

KROS has been the topic of several other reports. Truist Financial lowered their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Oppenheimer lowered their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Finally, TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

Shares of Keros Therapeutics stock opened at $11.01 on Friday. The company’s 50-day moving average price is $12.64 and its 200-day moving average price is $39.79. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The company has a market cap of $445.98 million, a price-to-earnings ratio of -2.11 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Braidwell LP lifted its position in Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after acquiring an additional 1,187,199 shares during the period. Point72 Asset Management L.P. raised its holdings in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Lynx1 Capital Management LP bought a new position in Keros Therapeutics in the 4th quarter valued at approximately $8,612,000. Millennium Management LLC boosted its stake in Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after purchasing an additional 305,169 shares during the last quarter. Finally, Alkeon Capital Management LLC increased its holdings in shares of Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after purchasing an additional 298,694 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.